|
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
NRG-GY018 is nearing its accrual goal of 810 patients.
Depending on the rate of accrual, the study could close as early as next week.
This notice serves to inform sites that accrual is nearing completion and to expect closure to accrual once the target goal has been met.
| 
